KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Net Income (2016 - 2025)

Historic Net Income for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to -$48.9 million.

  • Biogen's Net Income fell 11833.52% to -$48.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year decrease of 2078.79%. This contributed to the annual value of $1.3 billion for FY2025, which is 2078.79% down from last year.
  • According to the latest figures from Q4 2025, Biogen's Net Income is -$48.9 million, which was down 11833.52% from $466.5 million recorded in Q3 2025.
  • In the past 5 years, Biogen's Net Income registered a high of $1.1 billion during Q3 2022, and its lowest value of -$68.3 million during Q3 2023.
  • Moreover, its 5-year median value for Net Income was $391.0 million (2024), whereas its average is $436.9 million.
  • In the last 5 years, Biogen's Net Income soared by 153848.17% in 2022 and then tumbled by 11833.52% in 2025.
  • Biogen's Net Income (Quarter) stood at -$38.2 million in 2021, then skyrocketed by 1538.48% to $549.5 million in 2022, then crashed by 54.7% to $248.9 million in 2023, then grew by 7.15% to $266.7 million in 2024, then tumbled by 118.34% to -$48.9 million in 2025.
  • Its Net Income was -$48.9 million in Q4 2025, compared to $466.5 million in Q3 2025 and $634.8 million in Q2 2025.